← All trials
NCT05211895
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 18, 2022
- Primary completion
- Jun 2, 2027
- Completion date
- Sep 28, 2029
- First posted
- Jan 27, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 860
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Arcus Biosciences, Inc.Collaborator
- National Cancer Center, JapanOverall official - principal investigator
- Shandong UniversityOverall official - principal investigator
- National Cancer Center, JapanOfficial
- Shandong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.